BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33292277)

  • 1. FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A.
    Yu H; Xu Z; Guo M; Wang W; Zhang W; Liang S; Xu Z; Ye J; Zhu G; Zhang C; Lin J
    Cancer Cell Int; 2020 Nov; 20(1):545. PubMed ID: 33292277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.
    Khongkow P; Gomes AR; Gong C; Man EP; Tsang JW; Zhao F; Monteiro LJ; Coombes RC; Medema RH; Khoo US; Lam EW
    Oncogene; 2016 Feb; 35(8):990-1002. PubMed ID: 25961928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.
    Li X; Yao R; Yue L; Qiu W; Qi W; Liu S; Yao Y; Liang J
    J Cell Mol Med; 2014 May; 18(5):811-23. PubMed ID: 24628949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
    Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
    Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1/KIF20A axis promotes clear cell renal cell carcinoma progression via regulating EMT signaling and affects immunotherapy response.
    Fang K; Gong M; Liu D; Liang S; Li Y; Sang W; Zhu R
    Heliyon; 2023 Dec; 9(12):e22734. PubMed ID: 38125441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK/mTOR-mediated autophagy.
    Lin JZ; Wang WW; Hu TT; Zhu GY; Li LN; Zhang CY; Xu Z; Yu HB; Wu HF; Zhu JG
    Cancer Lett; 2020 Jan; 469():481-489. PubMed ID: 31738958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosis.
    Shi C; Huang D; Lu N; Chen D; Zhang M; Yan Y; Deng L; Lu Q; Lu H; Luo S
    Oncotarget; 2016 May; 7(18):26206-19. PubMed ID: 27036048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel.
    Li X; Qiu W; Liu B; Yao R; Liu S; Yao Y; Liang J
    J Transl Med; 2013 Sep; 11():204. PubMed ID: 24004449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin F and KIF20A, FOXM1 target genes, increase proliferation and invasion of ovarian cancer cells.
    Li Y; Guo H; Wang Z; Bu H; Wang S; Wang H; Fang H; Liu Z; Kong B
    Exp Cell Res; 2020 Oct; 395(2):112212. PubMed ID: 32771525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXM1 regulates radiosensitivity of lung cancer cell partly by upregulating KIF20A.
    Xiu G; Sui X; Wang Y; Zhang Z
    Eur J Pharmacol; 2018 Aug; 833():79-85. PubMed ID: 29704495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer.
    Zhang Z; Chai C; Shen T; Li X; Ji J; Li C; Shang Z; Niu Y
    Dis Markers; 2019; 2019():4782730. PubMed ID: 31565099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription.
    Liu Y; Liu Y; Yuan B; Yin L; Peng Y; Yu X; Zhou W; Gong Z; Liu J; He L; Li X
    Oncotarget; 2017 Mar; 8(10):17027-17037. PubMed ID: 28199985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
    Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
    Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
    Liu X; Xie T; Mao X; Xue L; Chu X; Chen L
    Cell Physiol Biochem; 2016; 39(2):617-29. PubMed ID: 27415661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer.
    Li H; Zhang W; Sun X; Chen J; Li Y; Niu C; Xu B; Zhang Y
    Cancer Manag Res; 2018; 10():3433-3450. PubMed ID: 30254487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
    Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
    Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3.
    Zhang Z; Bu H; Yu J; Chen Y; Pei C; Yu L; Huang X; Tan G; Tan Y
    Theranostics; 2019; 9(10):2882-2896. PubMed ID: 31244930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.